Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (12)

Cough (6)

Dyspnea (3)

Pneumonia (3)

Diarrhea (2)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 12
    records per page




    Kawasaki Disease MESHD Outbreak in Children TRANS During COVID-19 Pandemic.

    Authors: Ewelina Gowin; Jacek Wysocki; Magdalena Frydrychowicz; Danuta Januszkiewicz-Lewandowska

    doi:10.21203/rs.3.rs-70123/v1 Date: 2020-09-01 Source: ResearchSquare

    BackgroundIn response to the recent information about the outbreak of Kawasaki disease MESHD ( KD MESHD) in children TRANS connected to SARS-Cov-2 pandemic, we would like to present a group of six patients hospitalized from March to May 2020 with an inflammatory disease similar to KD MESHD. Findings There were four girls and two boys, aged TRANS from 15 months to 16 years. They all presented with fever HP fever MESHD lasting at least five days, irritability HP irritability MESHD, bilateral nonexudative conjunctivitis HP conjunctivitis MESHD, lymphadenopathy, mucus membrane changes, rash MESHD, edema HP edema MESHD.Neither the patients nor the other members of the patients' households had a positive history of COVID-19 infection MESHD. None of the six children TRANS had a positive PCR result for SARS-CoV-2 or a positive results for antibodies to SARS-CoV-2 SERO. All patients received empiric antibiotic therapy. Four patients were diagnosed with KD MESHD. Three children TRANS received standard treatment. One boy did not respond and received an additional 14-days course of methylprednisolone.In two girls, the diagnosis of KD MESHD was not made. All patients survived ConclusionFinding a correlation with the Covid-19 pandemic is difficult regarding the situation in our country. According to ECDC, in May 2020 Poland wass still before the peak of the epidemy. The intention of this article is to report that increased hospitalization of children TRANS with the inflammatory syndrome MESHD is also observed in countries with low levels of transmission TRANS of the SARS-Cov-2 virus. Our observation may broaden the knowledge of new inflammatory syndrome MESHD, which is not necessarily caused by SARS-Cov-2 but may be worsened by co-infection MESHD.

    Robust, reproducible clinical patterns in hospitalised patients with COVID-19

    Authors: Jonathan E Millar; Lucile Neyton; Sohan Seth; Jake Dunning; Laura Merson; Srinivas Murthy; Clark D Russell; Sean Keating; Maaike Swets; Carole H Sudre; Timothy D Spector; Sebastien Ourselin; Claire J Steves; Jonathan Wolf; - ISARIC4C Investigators; Annemarie B Docherty; Ewen M Harrison; Peter JM Openshaw; Malcolm G Semple; J Kenneth Baillie

    doi:10.1101/2020.08.14.20168088 Date: 2020-08-16 Source: medRxiv

    Severe COVID-19 is characterised by fever HP fever MESHD, cough HP cough MESHD, and dyspnoea MESHD. Symptoms affecting other organ systems have been reported. The clinical associations of different patterns of symptoms can influence diagnostic and therapeutic decision-making: for example, significant differential therapeutic effects in sub-groups of patients with different severities of respiratory failure HP respiratory failure MESHD have already been reported for the only treatment so far shown to reduce mortality in COVID-19, dexamethasone. We obtained structured clinical data on 68914 patients in the UK (the ISARIC Coronavirus Clinical Characterisation Consortium, 4C) and used a principled, unsupervised clustering approach to partition the first 33468 cases according to symptoms reported at recruitment. We validated our findings in a second group of 35446 cases recruited to ISARIC-4C, and in separate cohort of community cases. A core symptom set of fever HP fever MESHD, cough HP cough MESHD, and dyspnoea co MESHD-occurred with additional symptoms in three patterns: fatigue HP fatigue MESHD and confusion HP confusion MESHD, diarrhoea and vomiting MESHD vomiting HP, or productive cough HP. Presentations with a single reported symptom of dyspnoea MESHD or confusion HP confusion MESHD were common, and a subgroup of patients reported few or no symptoms. Patients presenting with gastrointestinal symptoms MESHD were more commonly female TRANS, had a longer duration of symptoms before presentation, and had lower 30-day mortality. Patients presenting with confusion HP confusion MESHD, with or without core symptoms, were older and had a higher unadjusted mortality. Symptom clusters were highly consistent in replication analysis using a further 35446 individuals subsequently recruited to ISARIC-4C. Similar patterns were externally verified in 4445 patients from a study of self-reported symptoms of mild disease. The large scale of ISARIC-4C study enabled robust, granular discovery and replication of patient clusters. Clinical interpretation is necessary to determine which of these observations have practical utility. We propose that four patterns are usefully distinct from the core symptom groups: gastro-intestinal disease MESHD, productive cough HP, confusion HP confusion MESHD, and pauci-symptomatic presentations. Importantly, each is associated with an in-hospital mortality which differs from that of patients with core symptoms. These observations deepen our understanding of COVID-19 and will influence clinical diagnosis, risk prediction, and future mechanistic and clinical studies.

    COVID-19 among people living with HIV MESHD: A systematic review

    Authors: Hossein Mirzaei; Willi McFarland; Mohammad Karamouzian; Hamid Sharifi

    doi:10.1101/2020.07.11.20151688 Date: 2020-07-14 Source: medRxiv

    This systematic review summarizes the evidence on the earliest patients with COVID-19-HIV co-infection MESHD. We searched PubMed, Scopus, Web of Science, Embase, preprint databases, and Google Scholar from December 01, 2019 to June 1, 2020. From an initial 547 publications and 75 reports, 25 studies provided specific information on COVID-19 patients living with HIV MESHD. Studies described 252 patients, 80.9% were male TRANS, mean age TRANS was 52.7 years, and 98% were on ART. Co-morbidities in addition to HIV and COVID-19 (multimorbidity) included hypertension HP hypertension MESHD (39.3%), obesity HP obesity MESHD or hyperlipidemia HP (19.3%), chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD (18.0%), and diabetes MESHD (17.2%). Two-thirds (66.5%) had mild to moderate symptoms, the most common being fever HP fever MESHD (74.0%) and cough HP (58.3%). Among patients who died, the majority (90.5%) were over 50 years old, male TRANS (85.7%), and had multimorbidity (64.3%). Our findings highlight the importance of identifying co-infections MESHD, addressing co-morbidities, and ensuring a secure supply of ART for PLHIV during the COVID-19 pandemic.

    Co-infection of SARS-COV-2 MESHD and influenza A virus: a case series and fast review

    Authors: Xuan Xiang; Zi-Hao Wang; Xin-Liang He; Xiao-Shan Wei; Yan-Ling Ma; Hui Li; Long Chen; Xiao-Rong Wang; Qiong Zhou

    doi:10.21203/rs.3.rs-35861/v1 Date: 2020-06-16 Source: ResearchSquare

    Background: COVID-19 has become a global pandemic. Studies about SARS-CoV-2 co-infection MESHD with influenza A virus (IAV) in the influenza season will contribute to the antiviral interventions of co-infected MESHD patients.Methods: A cohort of 145 COVID-19 patients in Wuhan union hospital were reviewed and we found 2 patients were co-infected MESHD with both SARS-CoV-2 and IAV. Then we searched from PubMed, Web of Science and CNKI with combinations of the following key words: “COVID-19, SARS-COV-2, influenza A and co-infection MESHD” from January 1 up to May 1, and 6 studies were included in this descriptive analysis. Results: Of the 13 co-infected MESHD patients, 2 were from Wuhan union hospital, another 11 were collected from the reports published on PubMed, Web of Science and CNKI. Of the 13 patients, the median age TRANS was 50 years (IQR, 40.5-67.5). Among the 13 patients, 7 (53.8%) were severe types. The most common symptoms among the 13 patients were cough HP cough MESHD (100%), fever HP fever MESHD (92.3%) and dyspnea HP dyspnea MESHD (76.9%). 8 patients had lymphocytopenia MESHD on admission and all the 13 patients had abnormal radiological changes. The median time from symptom onset TRANS to hospital admission was 4.5 days (IQR, 2.75-5.5), and the median time of hospital stay was 17 days (IQR,15-20). Conclusion: Patients with both SARS-COV-2 MESHD and IAV infection showed similar changes in symptoms and radiological images with patients infected with SARS-COV-2 only.   SARS-COV-2 co-infection MESHD with IAV can lead to more severe clinical condition but had similar hospital stay compared with patients infected with SARS-COV-2 only in the fast review.

    Clinical Characteristics and Comparative Analysis of Covid-19 Patients With or Without HIV Coinfection MESHD in Wuhan, China

    Authors: Rongrong Yang; Xien Gui; Yongxi Zhang; Yong Xiong; Shicheng Gao; Hengning Ke

    doi:10.21203/rs.3.rs-34735/v1 Date: 2020-06-12 Source: ResearchSquare

    Background: COVID-19 is a public health emergency that is spreading worldwide and seriously affecting global economy. Information about the impact of HIV co-infection MESHD and anti-HIV drugs on the clinical characteristics and prognosis of COVID-19 patients remains limited.Methods: In this retrospective study, the maximum body temperatures, fever HP fever MESHD duration, chest computed tomography changes and viral shedding, lymphocyte counts changes and titer of SARS-CoV-2 antibody SERO were compared between COVID-19 patients with and without HIV infection MESHD in Zhongnan Hospital of Wuhan University from January 20th to February 14th, 2020. Results: Compared with 50 control COVID-19 patients, the two COVID-19/ HIV co-infection MESHD patients had higher maximum body temperatures(40.2℃ and 40.3℃ vs 38.2℃), longer fever HP fever MESHD duration(11 days and 15 days vs 7 days), longer time of lung recovery(20 days and 24 days vs 14 days), shorter duration of viral shedding after the onset of symptoms TRANS(6 days and 4 days vs 10 days). Compared with three COVID-19 infection MESHD colleagues who had exposure history with the same COVID-19 patient, the third COVID-19/ HIV co-infection MESHD patient had the same duration of viral shedding after exposure(29 days vs 29 days), lower titer of SARS-CoV-2 IgG MESHD(negative vs positive for all). Conclusion: For patients co-infected MESHD with HIV MESHD, the clinical manifestations of SARS-CoV-2 infection MESHD were diverse. The ability of those COVID-19/ HIV co-infection MESHD patients with severe immunodeficiency HP immunodeficiency MESHD to produce SARS-CoV-2 antibodies SERO were weakened. The small sample in this study implied that the effects of anti-HIV drugs in prevention and treatment of COVID-19 appears to be limited.

    Fatal Central Nervous System Co-Infection MESHD with SARS-CoV-2 and Tuberculosis MESHD in a Healthy Child TRANS

    Authors: Bishara J. Freij; Bassam M. Gebara; Rabail Tariq; Ay-Ming Wang; John Gibson; Nidal El-Wiher; Graham Krasan; Paul M. Patek; Kelly A. Levasseur; Mitual Amin; Joseph M. Fullmer

    doi:10.21203/rs.3.rs-33272/v1 Date: 2020-06-04 Source: ResearchSquare

    Background. Central and peripheral nervous system symptoms MESHD and complications are being increasingly recognized among individuals with pandemic SARS-CoV-2 infections MESHD, but actual detection of the virus or its RNA in the central nervous system has rarely been sought or demonstrated. Severe or fatal illnesses are attributed to SARS-CoV-2, generally without attempting to evaluate for alternative causes or co-pathogens.Case presentation. A five-year-old girl with fever HP fever MESHD and headache HP headache MESHD was diagnosed with acute SARS-CoV-2-associated meningoencephalitis MESHD based on the detection of its RNA on a nasopharyngeal swab, cerebrospinal fluid analysis, and magnetic resonance imaging findings. Serial serologic tests SERO for SARS-CoV-2 IgG and IgA showed seroconversion, consistent with an acute infection MESHD. Mental status and brain imaging findings gradually worsened despite antiviral therapy and intravenous dexamethasone. Decompressive suboccipital craniectomy for brain herniation with cerebellar biopsy on day 30 of illness, shortly before death, revealed SARS-CoV-2 RNA in cerebellar tissue using the Centers for Disease Control and Prevention 2019-nCoV Real-Time Reverse Transcriptase-PCR Diagnostic Panel. On histopathology, necrotizing granulomas MESHD granulomas HP with numerous acid-fast bacilli were visualized, and Mycobacterium tuberculosis MESHD complex DNA was detected by PCR. Ventricular cerebrospinal MESHD fluid that day was negative for mycobacterial DNA. She had no known exposures to tuberculosis MESHD and no chest radiographic findings to suggest it. All 6 family members TRANS had normal chest radiographs and negative interferon-γ release assay results. The source of her tuberculous infection MESHD was not identified, and further investigations by the local health department were not possible because of the State of Michigan-mandated lockdown for control of SARS-CoV-2 spread.Conclusion. The detection of SARS-CoV-2 RNA in cerebellar tissue and the demonstration of seroconversion in IgG and IgA assays was consistent with acute SARS-CoV-2 infection of the central nervous infection MESHD. However, the cause of death MESHD was brain herniation from her rapidly progressive central nervous system tuberculosis MESHD. SARS-CoV-2 may mask or worsen occult tuberculous infection MESHD infection with severe HP or fatal consequences.

    Prevalence SERO, clinical characteristics and treatment outcomes of HIV MESHD and SARS-CoV-2 co-infection MESHD: a systematic review and meta-analysis

    Authors: Joseph Baruch Baluku; Ronald Olum; Curthbert Agolor; Josephine Nakakande; Laura Russell; Felix Bongomin; Jane Nakaweesi

    doi:10.1101/2020.05.31.20118497 Date: 2020-06-03 Source: medRxiv

    Objectives: To determine the prevalence SERO, clinical characteristics and outcomes of HIV MESHD and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection MESHD. Methods: We searched Medline, Embase, Cochrane and Web of Science databases and grey literature for studies reporting epidemiological and clinical data of patients with HIV MESHD and SARS-CoV-2 co-infection MESHD. Eligible studies were all observational or interventional studies and commentaries in English language that reported patient data on HIV/SARS-CoV-2 co-infection MESHD. We used random effect meta-analysis to determine the pooled prevalence SERO and mortality. Results: Of the 17 eligible studies, there were 3 retrospective cohorts, 1 survey, 5 case series, 7 case reports and 1 commentary that reported on a total of 146 HIV infected MESHD individuals. The pooled prevalence SERO of HIV among individuals with SARS-CoV-2 infection MESHD was 1.0% (95% CI: 0.0 - 3.0, I2 = 79.3%, p=0.01), whereas the prevalence SERO of SARS-CoV-2 among HIV patients was 0.68% (95% CI: 0.34 - 1.34). There were 110 (83.8%) HIV MESHD/ SARS-CoV-2 co-infected males MESHD males TRANS, and the age TRANS (range) of the co-infected MESHD was 30 - 60 years. A total of 129 (97.0%) were anti-retroviral therapy experienced, and 113 (85.6%) had a suppressed HIV viral load. The CD4 count (range) was 298 - 670 cells/mm3 (n = 107). The commonest symptoms were fever HP fever MESHD (73.5%, n=75) and cough HP (57.8%, n = 59). Sixty-two (65.3%) patients had at least one other comorbid condition, of which hypertension HP hypertension MESHD (26.4%, n = 38) was the commonest. Chest radiological imaging abnormalities were found in 46 (54.1%) cases. Twenty-eight cases (56.0%) were reported as mild. Recovery occurred in 120 (88.9%) cases, and the pooled mortality was 9% (95% CI: 3.0 - 15.0, I2 = 25.6%, p =0.24). Conclusion: The prevalence SERO of HIV/SARS-CoV-2 co-infection MESHD was low. The clinical characteristics and outcomes of HIV/SARS-CoV-2 co-infection MESHD are comparable to those reported among HIV negative SARS-CoV-2 cases.

    Co-infection of COVID-19 and Influenza A in A Hemodialysis Patient: A Case Report

    Authors: Ran Jing; Rama R Vunnam; Elizabeth Schnaubelt; Chad Vokoun; Allison Cushman-Vokoun; David Goldner; Srinivas R Vunnam

    doi:10.21203/rs.3.rs-31135/v1 Date: 2020-05-22 Source: ResearchSquare

    Background: Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel coronavirus that was first discovered in Wuhan, China in December 2019. With the growing numbers of community spread cases worldwide, the World Health Organization (WHO) declared the COVID-19 outbreak as a pandemic on March 11. Like influenza viruses, SARS-CoV-2 is thought to be transmitted by contact, droplets, and fomites, and COVID-19 has a similar disease presentation to influenza. Here we present a case of influenza A and COVID-19 co-infection MESHD in a 60-year-old man with end-stage renal disease MESHD ( ESRD MESHD) on hemodialysis.Case presentation: A 60-year-old man with ESRD MESHD on hemodialysis (HD) presented for worsening cough HP cough MESHD, shortness of breath MESHD, and diarrhea HP diarrhea MESHD. The patient first developed a mild fever HP fever MESHD (100 °F) during hemodialysis three days prior to presentation and has been experiencing worsening flu-like symptoms, including fever HP of up to 101.6 °F, non- productive cough HP, generalized abdominal pain HP abdominal pain MESHD, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, and liquid green diarrhea HP diarrhea MESHD. He lives alone at home with no known sick contacts and denies any recent travel TRANS or visits to healthcare facilities other than the local dialysis center. Rapid flu test was positive for influenza A. Procalcitonin was elevated at 5.21 ng/mL with a normal white blood SERO cell (WBC) count. Computed tomography (CT) chest demonstrated multifocal areas of consolidation and extensive mediastinal and hilar adenopathy MESHD concerning for pneumonia HP pneumonia MESHD. He was admitted to the biocontainment unit of Nebraska Medicine for concerns of possible COVID-19 and was started on oseltamivir for influenza and vancomycin/cefepime for the probable bacterial cause of his pneumonia HP pneumonia MESHD and diarrhea HP diarrhea MESHD. GI MESHD pathogen panel and C. diff toxin assay were negative. On the second day of admission, initial nasopharyngeal swab came back positive for SARS-CoV-2 by RT-PCR. The patient received supportive care and resumed bedside hemodialysis in strict isolation, and eventually fully recovered from COVID-19.Conclusions: Our case demonstrated that co-infection of influenza and SARS-CoV-2 can occur in patients with no known direct exposure to COVID-19. The possibility of SARS-CoV-2 co-infection MESHD should not be overlooked even when other viruses including influenza can explain the clinical symptoms.

    Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness MESHD: a comparison of patients with and without COVID-19

    Authors: Sachin J Shah; Peter N Barish; Priya A Prasad; Amy L Kistler; Norma Neff; Jack Kamm; Lucy M Li; Charles Y Chiu; Jennifer M Babick; Margaret C Fang; Yumiko Abe-Jones; Narges Alipanah; Francisco N Alvarez; Olga B Botvinnik; Jennifer M Davis; Gloria D Castenada; CLIAHub Consortium; Rand M Dadasovich; Xianding Deng; Joseph L DeRisi; Angela M Detweiler; Scot Federman; John R Haliburton; Samantha L Hao; Andrew D Kerkhoff; Renuka Kumar; Katherine Malcolm; Sabrina A Mann; Sandra P Martinez; Rupa Marya; Eran Mick; Lusajo L Mwakibete; Nader Najafi; Michael J Peluso; Maira S Phelps; Angela O Pisco; Kalani Ratnasiri; Luis A Rubio; Anna B Sellas; Kyla D Sherwood; Jonathan Sheu; Natasha Spottiswoode; Michelle Tan; Guixa Yu; Kirsten N Kangelaris; Charles Langelier

    doi:10.1101/2020.05.02.20082461 Date: 2020-05-06 Source: medRxiv

    Background: Emerging data on the clinical presentation, diagnostics, and outcomes of patients with COVID-19 have largely been presented as case series. Few studies have compared these clinical features and outcomes of COVID-19 to other acute respiratory illnesses. Methods: We examined all patients presenting to an emergency department in San Francisco, California between February 3 and March 31, 2020 with an acute respiratory illness MESHD who were tested for SARS-CoV-2. We determined COVID-19 status by PCR and metagenomic next generation sequencing (mNGS). We compared demographics, comorbidities, symptoms, vital signs, and laboratory results including viral diagnostics using PCR and mNGS. Among those hospitalized, we determined differences in treatment (antibiotics, antivirals, respiratory support) and outcomes (ICU admission, ICU interventions, acute respiratory distress syndrome MESHD respiratory distress HP syndrome, cardiac injury MESHD). Findings: In a cohort of 316 patients, 33 (10%) tested positive for SARS-CoV-2; 31 patients, all without COVID-19, tested positive for another respiratory virus (16%). Among patients with additional viral testing, no co-infections MESHD with SARS-CoV-2 were identified by PCR or mNGS. Patients with COVID-19 reported longer symptoms duration (median 7 vs. 3 days), and were more likely to report fever HP fever MESHD (82% vs. 44%), fatigue HP fatigue MESHD (85% vs. 50%), and myalgias HP myalgias MESHD (61% vs 27%); p<0.001 for all comparisons. Lymphopenia HP Lymphopenia MESHD (55% vs 34%, p=0.018) and bilateral opacities on initial chest radiograph (55% vs. 24%, p=0.001) were more common in patients with COVID-19. Patients with COVID-19 were more often hospitalized (79% vs. 56%, p=0.014). Of 186 hospitalized patients, patients with COVID-19 had longer hospitalizations (median 10.7d vs. 4.7d, p<0.001) and were more likely to develop ARDS (23% vs. 3%, p<0.001). Most comorbidities, home medications, signs and symptoms, vital signs, laboratory results, treatment, and outcomes did not differ by COVID-19 status. Interpretation: While we found differences in clinical features of COVID-19 compared to other acute respiratory illnesses MESHD, there was significant overlap in presentation and comorbidities. Patients with COVID-19 were more likely to be admitted to the hospital, have longer hospitalizations and develop ARDS, and were unlikely to have co-existent viral infections. These findings enhance understanding of the clinical characteristics of COVID-19 in comparison to other acute respiratory illnesses.

    Pregnancy outcomes, Newborn complications and Maternal-Fetal Transmission TRANS of SARS-CoV-2 in women with COVID-19: A systematic review

    Authors: Rahul Gajbhiye; Deepak Modi; Smita Mahale

    doi:10.1101/2020.04.11.20062356 Date: 2020-04-15 Source: medRxiv

    Abstract Objective: The aim of this systematic review was to examine published and preprint reports for maternal and fetal outcomes in pregnant women with COVID-19 and also assess the incidence of maternal-fetal transmission TRANS of SARS CO-V-2 infection MESHD. Design : Systematic review Data sources:We searched PUMBED. Medline, Embase, MedRxiv and bioRxiv databases upto 31st March 2020 utilizing combinations of word variants for " coronavirus " or " COVID-19 " or " severe acute respiratory syndrome MESHD " or " SARS-COV-2 " and " pregnancy " . We also included data from preprint articles. Study selection : Original case reports and case series on pregnant women with a confirmed diagnosis of SARS-CoV-2 infection MESHD. Data extraction : We included 23 studies [China (20), USA (01), Republic of Korea (01) and Honduras, Central America (01) reporting the information on 172 pregnant women and 162 neonates. The primary outcome measures were maternal health characteristics and adverse pregnancy outcomes, neonatal outcomes and SARS-CoV-2 infection MESHD in neonates was extracted. Treatments given to pregnant women with COVID-19 were also recorded. Results: Out of 172 women affected by COVID-19 in pregnancy, 160 women had delivered 162 newborns (2 set of twins, 12 ongoing pregnancies). In pregnant women with COVID-19, the most common symptoms were fever HP fever MESHD (54%), cough HP (35%), myalgia HP myalgia MESHD (17%), dyspnea HP dyspnea MESHD (12%) and diarrhea HP diarrhea MESHD (4%). Pneumonia HP was diagnosed by CT scan imaging in 100 % of COVID-19 pregnant women. Pregnancy complications included delivery by cesarean section (89%), preterm labor MESHD (21%), fetal distress HP (9%) and premature rupture of membranes HP (8%). The most common co-morbidities associated with pregnant women with COVID-19 were diabetes MESHD (11%), hypertensive disorders MESHD (9%), placental disorders MESHD (5%), co-infections MESHD (6%), scarred HP uterus (5%), hypothyroidism HP hypothyroidism MESHD (5%) and anemia HP anemia MESHD (4%). Amongst the neonates of COVID-19 mothers, preterm birth (23%), respiratory distress HP respiratory distress MESHD syndrome (14%), pneumonia HP pneumonia MESHD (14%) low birth weight (11%), small for gestational age HP age TRANS (3%) were reported. There was one still birth and one neonatal death MESHD reported. Vertical transmission TRANS rate of SARS-CoV-2 is estimated to be 11%. Conclusion In pregnant women with COVID-19, diabetes MESHD and hypertensive disorders MESHD are common co-morbidities and there is a risk of preterm delivery. Amongst the neonates born to mothers with COVID-19, respiratory distress HP respiratory distress MESHD syndrome and pneumonia HP pneumonia MESHD are common occurrence. There is an evidence of vertical transmission TRANS of SARS-CoV-2 infection MESHD in women with COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.